Shattuck Labs, Inc. (STTK), a clinical-stage biotechnology company, priced its previously announced public offering of 10.88 million shares at a price of $4 per share and pre-funded warrants to purchase up to 7.87 million shares at a price of $3.9999 per pre-funded warrant.
The aggregate gross proceeds from the offering are expected to be approximately $75 million, and the offering is expected to close on June 11, 2026, subject to closing conditions.
In addition, Shattuck has granted the underwriters an option to purchase up to an additional 2.81 million shares of its common stock at the public offering price for a period of 30 days.
Leerink Partners, J.P. Morgan, Piper Sandler and Cantor are acting as joint book-running managers for the proposed offering.
Shattuck Labs focuses on developing treatments for patients with inflammatory and immune-mediated diseases. Shattuck's lead investigational program, SL-325, is designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway in immune-mediated diseases.
STTK has traded between $0.71 and $8.33 over the last year. The stock closed Tuesday's trade at $4.27, up 9.49%.
In the pre-market, STTK is down 4.92% to $4.06.
For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.